Pharmaceuticals, Biotechnology and Life Sciences
Temedica GmbH has announced cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.
Sanofi and Blackstone (NYSE: BX) have announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM).
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for AstraZeneca’s Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, based in Heidelberg, Germany.
AYOXXA Biosystems GmbH has announced the successful closing of a financing round which will provide runway for the coming 3 – 5 years. The round was led by Hong Kong-based strategic investor, Prosnav Capital, who will provide AYOXXA access to the Asian market with a broad regional network. Besides Prosnav, a group of existing shareholders participated in the financing.
Arctoris and Evariste Technologies have formed a joint venture to identify novel small molecule kinase inhibitors for treatment of patients…
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have announced an update following the first analysis of the…
Novartis has announced new data that reinforce the transformational benefit of Zolgensma (onasemnogene abeparvovec), an essential one-time treatment for spinal muscular atrophy (SMA).
SeaBeLife has received €1.37M ($1.49M) in financing from Bpifrance. This financing, which has been granted in connection with the French government’s ‘Deeptech Plan’, will contribute to research into first-in-class drug candidates for the treatment of acute liver, kidney, heart and brain disease, SeaBeLife said in its press release.
The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet…